2. Search Result
Search Result
Isoforms Recommended: Oxazolidinone
Results for "

oxazolidinone

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

5

Biochemical Assay Reagents

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10394
    Linezolid
    Maximum Cited Publications
    52 Publications Verification

    PNU-100766

    		 Bacterial Antibiotic Infection Cancer
    Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics .
    Linezolid
  • HY-14855
    Tedizolid
    15+ Cited Publications

    TR 700; Torezolid; DA-7157

    		 Bacterial Antibiotic Infection
    Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
    Tedizolid
  • HY-19915
    Contezolid
    3 Publications Verification

    MRX-I

    		 Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) .
    Contezolid
  • HY-10392
    Sutezolid
    4 Publications Verification

    PNU-100480; U-100480; PF-02341272

    		 Bacterial Antibiotic Infection
    Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .
    Sutezolid
  • HY-111056
    UK122 TFA
    1 Publications Verification

    		 Ser/Thr Protease Cancer
    UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
    UK122 TFA
  • HY-100180
    Delpazolid
    1 Publications Verification

    LCB01-0371

    		 Bacterial Antibiotic Infection
    Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC90 of 2 μg/mL for both of them.
    Delpazolid
  • HY-W012982
    3-Amino-2-oxazolidinone
    1 Publications Verification

    AOZ

    		 Drug Metabolite Monoamine Oxidase Cardiovascular Disease Metabolic Disease
    3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as a indicator of furazolidone residues in vivo. 3-Amino-2-oxazolidinone is orally active .
    3-Amino-2-oxazolidinone
  • HY-100436
    Cadazolid

    ACT-179811

    		 Bacterial Antibiotic Infection
    Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.
    Cadazolid
  • HY-14800
    Radezolid
    10+ Cited Publications

    RX-1741

    		 Bacterial Antibiotic Infection
    Radezolid (RX-1741) is a oxazolidinone antibiotic. Radezolid is active against Staphylococcus, Chlamydia, and Legionella species, and remains active against Linezolid-resistant strains .
    Radezolid
  • HY-41882
    (S)-4-Benzyl-2-oxazolidone

    (-)-4-Benzyl-2-oxazolidinone

    		 Biochemical Assay Reagents Others
    (S)-4-Benzyl-2-oxazolidinone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Benzyl-2-oxazolidone
  • HY-139398
    TBI-223
    1 Publications Verification

    		 Antibiotic Bacterial Infection
    TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC50 of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis .
    TBI-223
  • HY-14855A
    (S)-Tedizolid
    2 Publications Verification

    (S)-TR 700; (S)-DA 7157

    		 Bacterial Antibiotic Infection
    (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
    (S)-Tedizolid
  • HY-W012982S
    3-Amino-2-oxazolidinone-d4

    AOZ-d4

    		 Isotope-Labeled Compounds Monoamine Oxidase Drug Metabolite Cardiovascular Disease Metabolic Disease
    3-Amino-2-oxazolidinone-d4 (AOZ-d4) is a deuterium labeled 3-Amino-2-oxazolidinone (HY-W012982). 3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as a indicator of furazolidone residues in vivo. 3-Amino-2-oxazolidinone is orally active .
    3-Amino-2-oxazolidinone-d4
  • HY-W007664
    (R)-4-Benzyl-2-oxazolidinone

    		Drug Intermediate Cytochrome P450 Cancer
    (R)-4-Benzyl-2-oxazolidinone is an oxazolidinone-type auxiliary that enables highly stereoselective asymmetric alkylation reactions. (R)-4-Benzyl-2-oxazolidinone is applied in the total synthesis of natural products and pharmaceutical preparations. Especially in pharmaceutical research and development, (R)-4-Benzyl-2-oxazolidinone not only serves as a key precursor for the synthesis of aromatase inhibitors, but also can be used in studies related to estrogen-dependent breast cancer .
    (R)-4-Benzyl-2-oxazolidinone
  • HY-10394R
    Linezolid (Standard)

    PNU-100766 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Linezolid (Standard) is the analytical standard of Linezolid. This product is intended for research and analytical applications. Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics .
    Linezolid (Standard)
  • HY-W002062
    (S)-4-Isopropyl-2-oxazolidinone

    		Biochemical Assay Reagents Others
    (S)-4-Isopropyl-2-oxazolidinone is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Isopropyl-2-oxazolidinone
  • HY-101819
    Antibacterial compound 1

    		Bacterial Infection
    Antibacterial compound 1 is a oxazolidinone extracted from patent WO1999037630A1 with antibacterial activities.
    Antibacterial compound 1
  • HY-101726
    DuP 105

    		Bacterial Infection
    DuP 105 is an orally active oxazolidinone with activity against Gram-positive bacteria. DuP 105 protects staphylococcal and streptococcal infections in mice. DuP 105 can be used for the study of infections caused by gram-positive bacteria .
    DuP 105
  • HY-19915A
    Contezolid acefosamil

    MRX-4

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Contezolid acefosamil (MRX-4) is the orally active proagent of the active antimicrobial metabolite Contezolid (MRX-I), an oxazolidinone which shows potent in vitro activity against various multidrug-resistant Gram-positive bacteria, including MRSA .
    Contezolid acefosamil
  • HY-19915B
    Contezolid acefosamil sodium

    MRX-4 sodium

    		 Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) .
    Contezolid acefosamil sodium
  • HY-10394S1
    Linezolid-d8

    PNU-100766-d8

    		 Antibiotic Bacterial Isotope-Labeled Compounds Infection
    PNU-100766-d8 is deuterated labeled Linezolid (HY-10394). Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics .
    Linezolid-d8
  • HY-135397
    (R)-​Linezolid

    (R)-PNU-100766

    		 Drug Metabolite Infection
    (R)-Linezolid is an impurity of Linezolid (PNU-100766). Linezolid, the first member of the class of oxazolidinone synthetic antibiotic, acts by inhibiting the initiation of bacterial protein synthesis .
    (R)-​Linezolid
  • HY-15993
    Posizolid

    AZD2563; AZD5847

    		 Antibiotic Infection
    Posizolid (AZD2563), an oxazolidinone antibiotic, is developed by AstraZeneca for the study of bacterial infections. Posizolid shows very good anti-mycobacterial activity .
    Posizolid
  • HY-W019727
    (S)-4-Phenyloxazolidin-2-one

    (S)-(+)-4-Phenyl-2-oxazolidinone

    		 Biochemical Assay Reagents Others
    (S)-4-Phenyloxazolidin-2-one is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Phenyloxazolidin-2-one
  • HY-111056A
    UK122 hydrochloride
    1 Publications Verification

    		 Ser/Thr Protease Cancer
    UK122 hydrochloride is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 hydrochloride shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50s > 100 μM). UK122 hydrochloride, a 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
    UK122 hydrochloride
  • HY-19428A
    Ranbezolid hydrochloride

    RBx-7644

    		 Antibiotic Bacterial Infection Cardiovascular Disease
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid hydrochloride
  • HY-19428
    Ranbezolid

    RBx7644 free base

    		 Antibiotic Bacterial Infection Cardiovascular Disease
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid
  • HY-W012982R
    3-Amino-2-oxazolidinone (Standard)

    AOZ (Standard)

    		 Reference Standards Monoamine Oxidase Drug Metabolite Cardiovascular Disease Metabolic Disease
    3-Amino-2-oxazolidinone (Standard) (AOZ (Standard)) is the analytical standard of 3-Amino-2-oxazolidinone (HY-W012982). This product is intended for research and analytical applications. 3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as a indicator of furazolidone residues in vivo. 3-Amino-2-oxazolidinone is orally active .
    3-Amino-2-oxazolidinone (Standard)
  • HY-167892
    DRF-8417

    		Antibiotic Bacterial Infection Inflammation/Immunology
    DRF-8417, an oxazolidinone antibiotic, is active against Gram-positive and fastidious Gram-negative bacteria. DRF 8417 exhibits potent activity against Gram-positive pathogens with MIC50 and MIC90 values ranging from 0.06 to 1 mg/L .
    DRF-8417
  • HY-138181
    Contezolid phosphoramidic acid

    MRX-I phosphoramidic acid

    		 Drug Intermediate Others
    Contezolid phosphoramidic acid is an intermediate in the synthesis of proagents of antibacterial oxazolidinone agent MRX-I. Contezolid phosphoramidic acid is extracted from patent WO2015127316A1, Intermediate 3, Method I .
    Contezolid phosphoramidic acid
  • HY-135397R
    (R)-?Linezolid (Standard)

    (R)-PNU-100766 (Standard)

    		 Drug Metabolite Reference Standards Infection
    (R)-​Linezolid (Standard) is the analytical standard of (R)-​Linezolid. This product is intended for research and analytical applications. (R)-Linezolid is an impurity of Linezolid (PNU-100766). Linezolid, the first member of the class of oxazolidinone synthetic antibiotic, acts by inhibiting the initiation of bacterial protein synthesis .
    (R)-?Linezolid (Standard)
  • HY-W750774
    (R)-4-Benzyl-3-propionyloxazolidin-2-one-d3

    N-3-propionyl-(4R)-benzyl-2-oxazolidinone-d3

    		 Isotope-Labeled Compounds Others
    (R)-4-Benzyl-3-propionyloxazolidin-2-one-d3 (N-3-propionyl-(4R)-benzyl-2-oxazolidinone-d3) is the deuterium labeled (R)-4-Benzyl-3-propionyloxazolidin-2-one (HY-W008773).
    (R)-4-Benzyl-3-propionyloxazolidin-2-one-d3
  • HY-10392R
    Sutezolid (Standard)

    PNU-100480 (Standard); U-100480 (Standard); PF-02341272 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Sutezolid (Standard) is the analytical standard of Sutezolid. This product is intended for research and analytical applications. Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis[1][2].
    Sutezolid (Standard)
  • HY-167841
    Anti-MRSA agent 19

    		Bacterial Antibiotic Infection
    Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against S. aureus. Anti-MRSA agent 19 is a active (median MIC=4 μg/mL) against 40 CDC isolates of different bacterial species containing various resistance factors，including Vancomycin (HY-B0671)，aminoglycoside/Tetracycline (HY-A0107)，and oxazolidinone resistance .
    Anti-MRSA agent 19
  • HY-101818
    PNU288034

    		Antibiotic Bacterial Infection
    PNU288034 is a potent oxazolidinone antibiotic.
    PNU288034
  • HY-125074
    PNU 142300

    		Drug Metabolite Infection
    PNU 142300 is an inactive metabolite of the oxazolidinone antibiotic Linezolid (HY-10394).
    PNU 142300
  • HY-W019727R
    (S)-4-Phenyloxazolidin-2-one (Standard)

    (S)-(+)-4-Phenyl-2-oxazolidinone (Standard)

    		 Biochemical Assay Reagents Reference Standards Others
    (S)-4-Phenyloxazolidin-2-one (Standard) is the analytical standard of (S)-4-Phenyloxazolidin-2-one. This product is intended for research and analytical applications. (S)-4-Phenyloxazolidin-2-one is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (S)-4-Phenyloxazolidin-2-one (Standard)
  • HY-10393R
    Eperezolid (Standard)

    PNU-100592 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Eperezolid (Standard) is an analytical standard for Eperezolid. This product is intended for research and analytical applications. Eperezolid (PNU-100592) is an oxazolidinone antibiotic with good in vitro inhibitory properties.
    Eperezolid (Standard)
  • HY-122123
    S-6123

    		Bacterial Antibiotic Infection
    S-6123 is a potent antimicrobial compound of the oxazolidinone series. S-6123 inhibits ribosomal protein synthesis without inhibiting DNA or RNA synthesis .
    S-6123
  • HY-100436R
    Cadazolid (Standard)

    ACT-179811 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Cadazolid (Standard) is the analytical standard of Cadazolid. This product is intended for research and analytical applications. Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.
    Cadazolid (Standard)
  • HY-113687
    T145

    		Bacterial Infection
    T145 is an oxazolidinone with antibacterial activity that inhibits growth of gram negatives (K. pneumoniae, A. baumannii, P. aeruginosa and E. cloacae), gram positives (E. faecalis and S. aureus) and acid fast pathogens (Mab, Mav and Mtb) .
    T145
  • HY-163486
    Antituberculosis agent-10

    		Bacterial Infection
    Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against Mycobacterium tuberculosis (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active .
    Antituberculosis agent-10
  • HY-14855AR
    (S)-Tedizolid (Standard)

    (S)-TR 700 (Standard); (S)-DA 7157 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    (S)-Tedizolid (Standard) is the analytical standard of (S)-Tedizolid. This product is intended for research and analytical applications. (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
    (S)-Tedizolid (Standard)
  • HY-14800R
    Radezolid (Standard)

    RX-1741 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Radezolid (Standard) is the analytical standard of Radezolid. This product is intended for research and analytical applications. Radezolid (RX-1741) is a oxazolidinone antibiotic. Radezolid is active against Staphylococcus, Chlamydia, and Legionella species, and remains active against Linezolid-resistant strains[1][2].
    Radezolid (Standard)
  • HY-14855R
    Tedizolid (Standard)

    TR 700 (Standard); Torezolid (Standard); DA-7157 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Tedizolid (Standard) is the analytical standard of Tedizolid. This product is intended for research and analytical applications. Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
    Tedizolid (Standard)
  • HY-14855S
    Tedizolid-13C,d3

    TR 700-13C,d3; Torezolid-13C,d3; DA-7157-13C,d3

    		 Isotope-Labeled Compounds Bacterial Antibiotic Infection
    Tedizolid- 13C,d3 is the 13C- and deuterium labeled Tedizolid. Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
    Tedizolid-13C,d3
  • HY-135397S
    (R)-Linezolid-d3

    		Isotope-Labeled Compounds Infection
    (R)-Linezolid-d3 ((R)-PNU-100766-d3) is the deuterium labeled (R)-Linezolid. (R)-Linezolid is an impurity of Linezolid (PNU-100766). Linezolid, the first member of the class of oxazolidinone synthetic antibiotic, acts by inhibiting the initiation of bacterial protein synthesis .
    (R)-Linezolid-d3
  • HY-10392S
    Sutezolid-13C4

    PNU-100480-13C4; U-100480-13C4; PF-02341272-13C4

    		 Isotope-Labeled Compounds Antibiotic Bacterial Infection
    Sutezolid- 13C4 (PNU-100480- 13C4) is 13C labeled Sutezolid. Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .
    Sutezolid-13C4
  • HY-160761
    K-Opioid receptor agonist-1

    		Opioid Receptor Inflammation/Immunology
    K-Opioid receptor agonist-1 (Compound 5a) is an agonist for κ-Opioid receptor with Ki of 0.25 nM and EC50 of 2 nM. K-Opioid receptor agonist-1 is blood brain barrier (BBB) penetrate (brain/plasma ratios of 0.50 to 0.65). K-Opioid receptor agonist-1 exhibits anti-inflammatory activity in dermatitis models induced by Arachidonic acid (HY-109590) or oxazolidinone .
    K-Opioid receptor agonist-1
  • HY-W003042R
    (S)-4-(4-Aminobenzyl)-2-oxazolidinone (Standard)

    		Reference Standards
    (S)-4-(4-Aminobenzyl)-2-oxazolidinone (Standard) is the analytical standard of (S)-4-(4-Aminobenzyl)-2-oxazolidinone. This product is intended for research and analytical applications.
    (S)-4-(4-Aminobenzyl)-2-oxazolidinone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: